ArticleAfrican journal of primary health care & family medicine2026
Diagnostic performance of the FluoroType MTBDR assay for rifampicin and isoniazid resistance in routine laboratory setting.
Article in African journal of primary health care & family medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Landscape of Molecular Diagnostic Tests and Emerging Tools for Tuberculosis and Drug Resistance.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-resistant tuberculosis (DR-TB) continues to be a major public health threat, especially in high-burden settings like South Africa. Rapid and accurate diagnosis of resistance to rifampicin (RIF) and isoniazid (INH) is essential to ensure that patients receive the right treatment as early as possible. Current diagnostic tools, though effective, have limitations. This study addresses the urgent need for faster, reliable alternatives to improve DR-TB detection.
aimThe aim of this study is to assess the performance of the FluoroType MTBDR assay in detecting resistance to RIF and INH in a real-world diagnostic setting.
settingThe study was carried out at the National Health Laboratory Services (NHLS) Polokwane Laboratory, a routine laboratory in Limpopo province, South Africa.
methodsWe tested 152 Mycobacterium tuberculosis (MTB) isolates collected from the 2023 laboratory repository using the FluoroType MTBDR version 2 assay. These results were compared with those from two established methods: GenoType MTBDRplus and Xpert MTB/RIF Ultra. Whole genome sequencing (WGS) was used to resolve any discrepancies, serving as the reference standard. Diagnostic accuracy was evaluated using sensitivity, specificity and predictive values.
resultsOf the 152 isolates, 65% were drug-resistant. FluoroType MTBDR showed excellent performance - 100% specificity and 96% sensitivity for RIF resistance and 91% sensitivity and 99% specificity for INH resistance - competing with the GenoType MTBDRplus.
conclusionFluoroType MTBDR offers a reliable, rapid alternative for detecting DR-TB, with the potential to improve timely diagnosis and treatment.Contribution: This study highlights the FluoroType MTBDR assay as a valuable diagnostic tool for routine use, contributing to improved TB control strategies, especially in resource-limited, high-burden settings, consistent with the journal's scope.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.